
Treanda: Uses, Dosage, Side Effects, Warnings - Drugs.com
Jul 22, 2024 · Treanda (bendamustine) is used to treat chronic lymphocytic leukemia and non-Hodgkin lymphoma. Includes Treanda side effects, interactions and indications.
TREANDA for Injection is indicated for the treatment of patients with indolent B-cell non-Hodgkin’s lymphoma that has progressed during or within six months of treatment with rituximab or a...
TREANDA or BENDEKA (bendamustine) - International Myeloma …
TREANDA® or BENDEKA® (bendamustine) is a type of chemotherapy FDA-approved to treat chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) in the …
Bendamustine - Wikipedia
Bendamustine, sold under the brand name Treanda among others, is a chemotherapy medication used in the treatment of chronic lymphocytic leukemia (CLL), multiple myeloma, and non …
Bendamustine (Treanda) - Uses, Side Effects, and More
Aug 29, 2025 · Find patient medical information for Bendamustine (Treanda) on WebMD including its uses, side effects and safety, interactions, pictures, warnings, and user ratings
DailyMed - TREANDA- bendamustine hydrochloride injection, …
Oct 27, 2022 · TREANDA (bendamustine hydrochloride) is an alkylating agent. The chemical name of bendamustine hydrochloride is 1H-benzimidazole-2-butanoic acid, 5- [bis (2 …
Treanda: Side effects, alternatives, uses, and more
Jul 17, 2024 · Treanda (bendamustine) is a prescription drug for certain types of cancer. It’s given as an infusion. Learn about side effects, alternatives, uses, and more.
Treanda - Chemocare
In general, drinking alcoholic beverages should be kept to a minimum or avoided completely while you are taking Treanda. You should discuss this with your doctor. Get plenty of rest. Maintain …
TREANDA Injection and TREANDA for Injection contain no antimicrobial preservative. The admixture should be prepared as close as possible to the time of patient administration.
Treanda (bendamustine) - Lymphoma Info
Treanda®, the trade name of bendamustine hydrochloride, is FDA approved for the treatment of indolent B-cell non-Hodgkin’s lymphoma that has not responded well to rituximab treatment.